Stock Report

All about this stock under one free report Last Updated: 03-Sep-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Clear All

Haemonetics (HAE) Key Ratios

Stock Card factsheet share-fund-plan-icon

$102.92

up-down-arrow $0.97 (0.95%)

As on 02-Sep-2026 16:00EDT

Market cap

info icon

$4,924 Mln

Revenue (TTM)

info icon

$1,352 Mln

P/E Ratio

info icon

52.3

P/B Ratio

info icon

5.9

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue -2.01 5.60 0.44 3.53 8.40
EBIT 306.62 -26.74 -42.21 -7.40 9.87
Net Profit 263.85 -3.00 -41.05 -11.00 8.35
EPS 265.71 2.62 -37.43 -8.32 10.27
Book Value -- -- 3.84 2.56 3.67
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMMar-26Mar-25
EBIT-Margin info 15.2414.1211.1811.7518.16
Net Margin info --7.227.12----
Return on equity info 14.7012.9311.0112.0318.83
Return on Capital info 6.876.17--4.798.79
Return on Assets info 5.645.073.434.027.22
Debt to Equity (x) info ----1.401.541.49

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Haemonetics (HAE)
--
4.79
8.79
7.01
7.41
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

11.01

Higher than Peers by 6.07

Profit after tax / Average Net worth * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Haemonetics (HAE)
11.01
12.03
18.83
13.22
14.72
Peer Median
4.94
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

3.43

Higher than Peers by 0.97

Profit after tax / Average Total assets * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Haemonetics (HAE)
3.43
4.02
7.22
5.69
6.08
Peer Median
2.45
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

11.18

Higher than Peers by 2.71

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Haemonetics (HAE)
11.18
11.75
18.16
15.80
14.31
Peer Median
8.47
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

7.12

Higher than Peers by 2.45

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Haemonetics (HAE)
7.12
7.29
12.32
8.98
10.00
Peer Median
4.68
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

--

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Haemonetics (HAE)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

0.44

Lower than Peers by 8.04

Year on year growth in net sales

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Haemonetics (HAE)
0.44
-0.02
0.04
0.12
0.18
Peer Median
8.49
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

-42.21

Lower than Peers by 52.86

Year on year growth in operating profit (EBIT)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Haemonetics (HAE)
-42.21
-36.57
19.47
23.71
58.98
Peer Median
10.65
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

-41.05

Lower than Peers by 54.60

Year on year growth in profit after tax

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Haemonetics (HAE)
-41.05
-41.97
42.64
1.87
166.05
Peer Median
13.55
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

-37.43

Lower than Peers by 57.93

Year on year growth in earnings per share

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Haemonetics (HAE)
-37.43
-0.38
0.48
0.01
1.67
Peer Median
20.51
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

0.38

Lower than Peers by 6.63

Year on year growth in book value per share

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Haemonetics (HAE)
0.38
--
--
--
--
Peer Median
7.01
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

1.40

Higher than Peers by 1.00

Total debt / Net worth

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Haemonetics (HAE)
1.40
1.54
1.49
0.84
0.94
Peer Median
0.40
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

0.01

--

(Short term borrowings / Net worth)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Haemonetics (HAE)
0.01
0.01
0.37
0.01
0.01
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

3.08

Higher than Peers by 0.26

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Haemonetics (HAE)
3.08
2.95
1.62
2.56
3.06
Peer Median
2.83
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

1.91

Lower than Peers by 0.13

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Haemonetics (HAE)
1.91
1.87
0.99
1.50
2.03
Peer Median
2.05
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

5.26

Higher than Peers by 0.30

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Haemonetics (HAE)
5.26
5.46
25.35
15.89
11.43
Peer Median
4.96
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

15.98

Lower than Peers by 0.47

Debtors outstanding / Net Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Haemonetics (HAE)
15.98
16.26
14.89
15.78
15.33
Peer Median
16.46
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.48

Lower than Peers by 0.02

Sales / Average Total Assets

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Haemonetics (HAE)
0.48
0.55
0.59
0.63
0.62
Peer Median
0.50
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Haemonetics (HAE)
--
57.43
54.92
53.81
52.90
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Haemonetics (HAE)
--
207.70
214.01
176.34
184.84
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Haemonetics (HAE)
--
36.51
44.02
41.99
40.92
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Haemonetics (HAE)
--
228.62
224.91
188.16
196.82
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

52.28

Higher than Peers by 7.82

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Haemonetics (HAE)
52.28
26.77
18.75
37.32
36.73
Peer Median
44.46
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

5.89

Higher than Peers by 2.10

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Haemonetics (HAE)
5.89
3.27
3.83
4.57
5.18
Peer Median
3.79
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Haemonetics (HAE)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

21.76

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Haemonetics (HAE)
21.76
11.47
11.41
16.97
18.73
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

4,924

Higher than Peers by 4,383

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Haemonetics (HAE)
4,924
--
--
--
--
Peer Median
540
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...